ArticleExperimental and therapeutic medicine2020
Ophiopogonin D attenuates PM2.5-induced inflammation via suppressing the AMPK/NF-κB pathway in mouse pulmonary epithelial cells.
Article in Experimental and therapeutic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- ATOJIN: A Natural Products Mixture, Alleviates Atopic Dermatitis in DNCB-Induced NC/Nga Mice.Mediators of inflammation · 2026Article
- Deacetyl Ophiopojaponin A ameliorates Asthma by Inhibiting L-Type Calcium Channel Cav2.3 to Reduce Calcium Load in Airway Epithelial Cells.Journal of inflammation research · 2026Article
- Ophiopogonin D Alleviates Nonalcoholic Steatohepatitis via Ferroptosis Through AKT1/STAT3/HIF-1α Axis.Analytical cellular pathology (Amsterdam) · 2026Article
- Ophiopogonin D Alleviates Sepsis-Induced Acute Lung Injury Through Improving Microvascular Endothelial Barrier Dysfunction via Inhibition of HIF-1α-VEGF Pathway.Cell biochemistry and biophysics · 2025Article
- PM2.5 Exposure Aggravates Inflammatory Response and Mucus Production in 16HBE Cells through Inducing Oxidative Stress and RAGE Expression.Cell biochemistry and biophysics · 2025Article
- Protective properties of Ophiopogonin D in DSS-induced colitis: insights into microbiota modulation.Inflammopharmacology · 2024Article
- Ophiopogonin D: review of pharmacological activity.Frontiers in pharmacology · 2024Review
- A Chinese classical prescription Maimendong decoction in treatment of pulmonary fibrosis: an overview.Frontiers in pharmacology · 2024Review
- Ophiopogonin D ameliorates non‑alcoholic fatty liver disease in high‑fat diet‑induced obese mice by improving lipid metabolism, oxidative stress and inflammatory response.Experimental and therapeutic medicine · 2023Article
- Systematic Investigation of the Effect ofFoods (Basel, Switzerland) · 2023Article
- Identification of Small Airway Epithelium-Related Hub Genes in Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2022Article
- A review of respirable fine particulate matter (PMFrontiers in molecular neuroscience · 2022Review
- The Correlation of PM2.5 Exposure with Acute Attack and Steroid Sensitivity in Asthma.BioMed research international · 2022Review
- Inhalation of Salvianolic Acid B Prevents Fine Particulate Matter-Induced Acute Airway Inflammation and Oxidative Stress by Downregulating the LTR4/MyD88/NLRP3 Pathway.Oxidative medicine and cellular longevity · 2022Article
- Isosinensetin alleviates the injury of human bronchial epithelial cells induced by PMExperimental and therapeutic medicine · 2021Article
- Pellino1 promoted inflammation in lung injury model of sepsis by TRAF6/ NF-κB signal pathway.Journal of inflammation (London, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure to fine particulate matter, such as particulate matter of ≤2.5 µm in diameter (PM2.5), causes pulmonary inflammation and injury to other organs. It has been reported that Ophiopogonin D (OP-D) has anti-inflammatory activity. The aim of the present study was to investigate this anti-inflammatory activity of OP-D on PM2.5-induced acute airway inflammation and its underlying mechanisms. The viability of PM2.5-treated mouse lung epithelial (MLE-12) cells with or without OP-D treatment was determined using a Cell Counting Kit-8 assay. The corresponding levels of IL-1β, IL-6, IL-8 and TNF-α were examined via ELISA. Subcellular localization of NF-κBp65 was detected using immunofluorescence staining. The expression levels of AMP-activated protein kinase (AMPK), phosphorylated (p)-AMPK, NF-κBp65 and p-NF-κBp65 were analyzed using western blotting. The selective AMPK inhibitor Compound C (CC) was utilized to investigate the involvement of AMPK in the protection against PM2.5-induced cell inflammation by OP-D treatment. The results demonstrated that OP-D significantly ameliorated the PM2.5-stimulated release of proinflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-8) and inhibited the translocation of NF-κBp65 from the cytoplasm to the nucleus in MLE-12 cells. Moreover, OP-D significantly prevented the PM2.5-triggered phosphorylation of NF-κBp65 and upregulated AMPK activity. The anti-inflammatory activity of OP-D could also be attenuated by the AMPK-specific inhibitor CC. The present results suggested that the anti-inflammatory activity of OP-D was mediated via AMPK activation and NF-κB signaling pathway downregulation, which ameliorated the expression of proinflammatory cytokines. Therefore, OP-D could be a candidate drug to treat PM2.5-induced airway inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.